Showing results (11-20 of 111) with videos related to
Sort By:
Pageof 12
Expert Review of Neurotherapeutics|December 3, 2013
Clinical case reviews in multiple sclerosis spasticity: experiences from around EuropeJürgen Koehler, Maria P Amato, Celia Oreja-Guevara, et al.Journal of Neuroimmunology|October 16, 2013
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosisMarkus Axelsson, Niklas Mattsson, Clas Malmeström, et al.The Journal of Antimicrobial Chemotherapy|September 11, 2019
An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational studyJohan Lindström, Anders Helldén, Jan Lycke, et al.Multiple Sclerosis and Related Disorders|February 21, 2021
Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillanceStina Kågström, Anna Fält, Anders Berglund, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2025
Quality of life is decreased in persons with relapsing-remitting multiple sclerosis experiencing progression independent of relapse activitySarah Lindberg, Sofia Sandgren, Markus Axelsson, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2021
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based studyIgal Rosenstein, Markus Axelsson, Lenka Novakova, et al.Journal of Neuroimmunology|May 10, 2011
The effect of live, attenuated measles vaccine and measles infection on measles antibody levels in serum and CSF of patients with multiple sclerosis or clinically isolated syndromeCecilia Ahlgren, Anders Odén, Sara Haghighi, et al.Journal of Neurology|November 26, 2015
Rituximab in paediatric onset multiple sclerosis: a case seriesJonatan Salzer, Jan Lycke, Ronny Wickström, et al.Neurodegenerative Disease Management|November 23, 2016
Country breakout session highlightsAngelo Ghezzi, Linard Filli, Claudio Solaro, et al.Journal of Neuroimmunology|March 4, 2014
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatmentClas Malmeström, Markus Axelsson, Jan Lycke, et al.Pageof 12